Purpose. Human papillomavirus (HPV) infection in women is known to promote the development of cervical neoplasia. Specific HPV genotypes are more highly associated with disease, and therefore detection and genotyping of HPV infection is critical for preventing and effectively treating cervical cancer. Consequently, various assays using diverse technologies have been developed to detect HPV genotype. Recently the OmniPlex-HPV and GeneFinder HPV methods, based on PCR and Luminex xMAP liquid bead microarray technologies, were developed for the detection of 40 and 32 HPV genotypes, respectively. The purpose of this study was to compare the clinical performance of OmniPlex-HPV and GeneFinder HPV.
INTRODUCTION
Human papillomaviruses (HPV) are double-stranded DNA viruses that infect the human genital tract [1] . Wholegenome sequence analysis has revealed more than 150 distinct HPV genotypes [2, 3] . However, the approximately 60 HPV genotypes that have been recognized are subdivided into high-risk (HR), probable high-risk (pHR) and low-risk (LR) groups [4] . HR HPV genotypes, including HPV 16 and 18, are closely associated with invasive cervical cancer, whereas LR HPV genotypes, such as HPV 6 and 11, promote the development of genital warts [5, 6] . Since infection with certain HPV genotypes increases the risk of cervical cancer, a sensitive and accurate HPV DNA detection and genotyping method is essential to aid in the diagnostic process for the treatment and prevention of disease. To address this need, a number of techniques have been devised with different targets, genotyping coverage, automation and throughput capacity [7] .
Recently two such assays for the detection of HPV genotypes were developed, the OmniPlex-HPV (Genematrix Inc., Seongnam, Republic of Korea) and GeneFinder HPV (Infopia Inc., Anyang, Republic of Korea) in vitro diagnostic reagents, both of which are based on amplification through the polymerase chain reaction (PCR) followed by Luminex xMAP liquid bead microarray (LBMA) technology. The OmniPlex-HPV test is designed to detect 40 HPV genotypes (15 h, 4 pHR and 21 LR types), and GeneFinder HPV to detect 32 HPV genotypes (19 h and 13 LR types) (Table 1 ) [8, 9] . The goal of this study was to compare the clinical performance of both methods on cytology-confirmed clinical cervical specimens. We found that both tests are highly accurate for the detection and genotyping of HPV infection, but OmniPlex-HPV shows greater sensitivity in cases of infection with multiple HPV genotypes, suggesting that this method is preferable in the clinical setting.
METHODS
Clinical specimens A total of 300 cervical swab specimens were collected between April 2016 and May 2017; these were subjected to concurrent cervical cytological examination and HPV genotyping assay at Samkwang Medical Laboratories. The study protocol was approved by the Institutional Review Board of Samkwang Medical Laboratories (17-01-10) . The cytological results and number of collected specimens in each category were as follows: normal (n=100), atypical squamous cells of undetermined significance (n=100), low-grade squamous intra-epithelial lesion (n=69) and high-grade squamous intra-epithelial lesion (n=31). Cervical swab specimens were placed into ThinPrep PreservCyt solution (Hologic Inc., Marlborough, MA, USA) and first prepared for liquid-based cytology examination. DNA was then extracted from the residual specimens using the MagNA Pure 96 System (Roche Molecular Systems Inc., NJ, USA), according to the manufacturer's instructions. Extracted DNA was stored at -70 C when not used immediately.
OmniPlex-HPV LBMA genotyping assay Purified DNA from cervical specimens was subjected to the OmniPlex-HPV assay (Genematrix Inc., Seongnam, Republic of Korea) as follows. HPV DNA was first amplified by single-closed tube nested PCR using the PCR master mix and a primer pool capable of amplifying 40 HPV genotypes. The human b-globin gene was co-amplified as an internal control. Amplified PCR products were then hybridized using 6.5 µm polystyrene microspheres embedded with magnetic particles (beads), which are internally dyed with specific intensities of red (CL1) and infrared (CL2) fluorophores. Each bead contains an oligonucleotide probe specific to one of 40 distinct HPV genotypes. Following hybridization between PCR products and beads, these were measured using the Luminex MAGPIX system (Luminex Corporation, Austin, TX, USA), which enables the simultaneous measurement of 40 HPV genotypes in a single reaction.
GeneFinder HPV LBMA assay The GeneFinder HPV assay (Infopia Inc., Anyang, Republic of Korea) was performed according to the manufacturer's instructions [8] . In brief, HPV DNA was amplified in two separate tubes using the PCR master mix and primers provided by the kit. Both amplified PCR mixtures were hybridized with 5.6 µm polystyrene microspheres embedded with magnetic beads which are internally dyed with specific intensities of red and infrared fluorophores, as described above. Each microsphere contains an oligonucleotide probe specific for one of 32 HPV genotypes. After hybridization between PCR products and beads, these were measured by the Luminex 200 System (Luminex Corporation), thus allowing the detection of 32 HPV genotypes in one reaction.
Type-specific sequencing of discordant HPV genotypes The results were termed concordant, compatible or discordant based on the following definitions: if the analyses yielded identical genotypes in both tests, the results were termed concordant; if one or more additional genotypes were not detected by either of the assays, the results were termed compatible; and if there were no similarities in the genotypes between the two assays, the results were termed discordant. As a gold standard method for validation, discordant HPV genotype results from the two different assays were resolved by performing type-specific direct sequencing analysis [10] [11] [12] . Briefly, PCR products amplified with the PGMY09/11 primer set were purified using the QIAquick PCR Purification Kit (QIAGEN, Hilden, Germany), according to the manufacturer's instructions. Purified PCR products were sequenced using the BigDye Terminator v3.1 
Statistical analysis
Agreement between HPV genotyping results from the two assays was assessed using Cohen's kappa coefficient test. The clinical sensitivity, specificity and odds ratios for each assay were determined by comparing the results of cytology and positive HR-HPV identification. All analyses were limited to the HPV genotypes or groups of genotypes (HR HPV) tested by both assays to ensure the most accurate comparison between the two tests [8, 13] . In general, k values >0.75 suggest excellent agreement, those between 0.40 and 0.75 suggest fair to good agreement and those <0.40 suggest poor agreement [14] . A test was regarded as statistically significant when the P-value was <0.05. All analyses, including Cohen's kappa coefficient test as well as sensitivity, specificity and odds ratios, were calculated using MedCalc ver. 17.8.6 (MedCalc Software, Ostend, Belgium).
RESULTS
A total of 300 cervical swab specimens were analysed using the OmniPlex-HPV and GeneFinder HPV assays. First, we compared the number of positive HPV genotype results obtained by each of the two assays. We found that OmniPlex-HPV detected HPV genotypes in 216 specimens (72.0 %), and GeneFinder HPV in 212 specimens (70.7 %). Of these, 171 (57.0 %) and 167 (55.7 %) specimens were found to be HR HPV positive by OmniPlex-HPV and GeneFinder HPV, respectively ( Direct sequencing analysis was then performed on the 121 compatible and discordant specimens; Table 4 shows the full direct sequencing results in all 121 cases. Concordant genotypes were defined as those cases where identical genotypes were detected by the two assays; we considered these results as true positives and did not perform further sequencing on these samples. Based on the genotype sequencing results, we found a total of 13 false-positive genotypes, comprising nine HR and four LR HPV genotypes in 11 specimens. OmniPlex-HPV returned false-positive results in three cases, for the LR HPV genotypes 61 and 87, (Table S1 , available in the online version of this article).
To identify the relationship between cervical lesion progression level and HR HPV positivity, a statistical analysis was performed on the four cytology subgroups: HSIL and worse (termed 'HSIL '), LSIL and worse (termed 'LSIL '), ASCUS and worse (termed 'ASCUS ') and normal histology (Table 5) . In Table S2 , we show the HR and LR HPV detection rates according to the histological group by OmniPlex-HPV and GeneFinder HPV. Cases with HSIL, LSIL and ASCUS cytology were defined as 'disease positive', and clinical sensitivity and specificity were calculated ( Critically, direct sequencing, which utilizes PGMY09/11 primers, is thought to be inefficient in the detection of multiple HPV-infected samples. Therefore, we further performed a second round of type-specific PCR for detecting various HPV genotypes among multiple HPV-infected samples [15] [16] [17] . A previous study calculated the GeneFinder HPV detection rate for multiple infection at 15.4 %, which was higher than the other assays examined [8] . In the present study, the OmniPlex-HPV assay was found to be more sensitive than GeneFinder HPV for analysing multiple genotype-infected samples, as shown in Table S1 . In addition, when direct sequencing was performed on HPV samples detected by OmniPlex-HPV, most genotypes were identified.
We further calculated diagnostic sensitivities and specificities for HR HPV positivity of the OmniPlex-HPV and GeneFinder HPV assays, including both HR and pHR HPV genotypes, based on cervical lesion cytology results. We found that the assays demonstrated comparable sensitivities, specificities and odds ratios. Overall, the odds ratios for developing SCC associated with HR HPV positivity were higher for OmniPlex-HPV than for GeneFinder HPV in HSIL, but odds ratios were similar in samples with LSIL and ASCUS cytology. A previous study found that DNAbased techniques, including Hybrid Capture II (HC II) and Real-time PCR, display high levels of clinical sensitivity and specificity for lesions with severe cytological grades [18] . In another study that compared HC II to Abbott RealTime HR based on real-time PCR, PANArray based on peptide acidbased array, and GeneFinder HPV based on LBMA, these techniques demonstrated high clinical concordance rates of 86.5, 85.7 and 93.2 %, respectively [8, 19] . In addition, this analysis found an 87.0 % agreement between Abbott RealTime HR and GeneFinder HPV and an 86.5 % agreement between PANArray with GeneFinder HPV, indicating high overall concordance rates among the various techniques. In our study, GeneFinder HPV, which has the highest agreement with HC II, showed a high agreement rate of 90.7 % with OmniPlex-HPV, indicating that OmniPlex-HPV is equivalent to GeneFinder HPV.
Our study has certain limitations. First, when assessing the relationship between HPV results and cervical lesion development, the odds ratio deviation for HSIL samples was quite large, likely due to the small sample size. In addition, direct sequencing was not performed for all samples but rather was carried out for only 121 compatible and discordant samples, as we assumed that concordant samples represented the true result in both assays.
In conclusion, our data show that the OmniPlex-HPV and GeneFinder HPV assays are highly comparable for the detection and genotyping of HPV in clinical samples, and both display high sensitivity and specificity for HR HPV detection in cervical lesions of various levels of severity. Furthermore, OmniPlex-HPV shows a higher accuracy for detecting multiple HPV infection and therefore it is more suitable for detecting and genotyping single and multiple HPV infections in cervical specimens. We also suggest that further study is needed to investigate the correlation between multiple HPV infection and clinical influence on a larger number of samples using OmniPlex-HPV.
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